Notizie e Video - BIOCARTIS - Inglese - Pagina 2

PRESS RELEASE 22 February 2023, 07:00 CET BIOCARTIS ANNOUNCES CHANGE IN BOARD COMPOSITION Mechelen , Belgium, 22 February 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Mr. Roald Borré has resigned as Director of the Company, and that upon the recommendation of the Company’s Remuneration and Nomination Committee, the Board of Directors has appointed Mr. Bryan Dechairo as new...

PRESS RELEASE - REGULATED INFORMATION 31 January 2023 , 1 7: 4 0 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium , 31 January 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of January 2023 a further portion of receivables due by the Company to Highbridge under the senior secured 'Facility Agreement' (as amended from time to time) ("First Lien Loan Agreement")...

PRESS RELEASE: REGULATED INFORMATION 4 January 2023, 17:40 CET Disclosure of transparency notification s Mechelen, Belgium, 4 January 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE: REGULATED INFORMATION 22 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen, Belgium, 22 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE: REGULATED INFORMATION 22 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen , Belgium , 22 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of December 2022: 33,476,932 new shares were issued following the successful completion of the capital increase through the offering of new shares (with extra-legal preferential rights for...

PRESS RELEASE: REGULATED INFORMATION 5 December 2022, 17:40 CET Mandatory Conversion Bondholder Notification Capitalised terms not otherwise defined in this notice shall have the meaning given to them in the Terms and Conditions of the Bonds. Mechelen, Belgium , 5 December 2022 – This announcement constitutes a notice (the “Mandatory Conversion Bondholder Notification”) in accordance with, respectively, Condition 5(m)(v) of the terms and conditions of the 4.00% convertible bonds due...

PRESS RELEASE: REGULATED INFORMATION 2 December 2022, 17:45 CET Disclosure of a transparency notification Mechelen, Belgium, 2 December 2022 – Biocartis Group NV (the " Company " or " Biocartis "), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down...

PRESS RELEASE: REGULATED INFORMATION 2 December 2022, 17:40 CET Disclosure of Outstanding Voting Securities Mechelen , Belgium , 2 December 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that following the successful completion of the capital increase through the offering of new shares (with extra-legal preferential rights for existing shareholders) that was announced on 16 November 2022 , its...

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 29 November 2022, 10:30 CET Biocartis Announces 55.91 % of Offered S hares S ubscribed at C losing of the R ights S ubscription P eriod for H olders of P referential R ights , and Start of the S ale of the S crips through a P rivate P lacement to I nstitutional In vestors Warning: An investment in the Company's ordinary shares (the "Shares" , including the Offered Shares (as defined below) and the new Shares issuable upon conversion of...

ADVERTISEMENT PRESS RELEASE : INSIDE INFORMATION / REGULATED INFORMATION 16 November 2022, 07:00 CET Biocartis launches a rights offering (with extra-legal preferential rights for existing shareholders) of a maximum of 33,476,932 offered shares, amounting to a maximum of EUR 25,107,699.00 Warning: An investment in the Company's ordinary shares (the "Shares" , including the Offered Shares (as defined below) and the new Shares issuable upon conversion of the Existing Convertible Bonds, upon...

PRESS RELEASE: REGULATED INFORMATION 31 October 2022, 07:00 CET Biocartis Announces Completion of Exchange Offer for its Existing Convertible Bonds, and issuance of New Convertible Bonds Mechelen, Belgium , 31 October 2022 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces the completion of the exchange offer for its 4.00% convertible bonds due 2024/2027 (the "Existing Convertible Bonds") thereby delivering on...

PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:01 CEST Biocartis Announces Conversion of a P ortion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities Mechelen, Belgium , 28 October 202 2 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that following the first drawdown by the Company under the new senior secured convertible term loan (“Convertible Term...

PRESS RELEASE: REGULATED INFORMATION 28 October 2022, 07:00 CEST Invitation to the Extraordinary Shareholders’ Meeting Mechelen, Belgium , 28 October 2022 – As the attendance quorum for certain items on the agenda of the extraordinary general shareholders' meeting ("EGM") of 27 October 2022 was not reached, Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of...

PRESS RELEASE : REGULATED INFORMATION 27 October 2022, 17:40 CEST Results of the Extraordinary Shareholders’ Meeting held on 27 October 2022 Mechelen, Belgium, 27 October 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), held its extraordinary general shareholders' meeting today. The proposed resolution referred to in item 7 of the agenda regarding the approval and ratification of the change of control...

PRESS RELEASE: 10 October 2022, 07:00 CEST Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients HepatoPredict helps identify Hepatocellular Carcinoma (HCC) patients that will benefit from a liver transplantation Primary liver cancer 1 is the sixth most common and third most lethal cancer in the world 2 Biocartis to initiate commercialization in Europe of HepatoPredict, a prognostic gene expression signature test developed by its partner...

PRESS RELEASE : REGULATED INFORMATION 27 September 2022, 07:00 CEST Invitation to the Extraordinary Shareholders ’ Meeting Mechelen, Belgium , 27 September 202 2 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its extraordinary shareholders' meeting (‘EGM’) which will...

PRESS RELEASE : REGULATED INFORMATION 26 September 2022, 07:40 CEST Biocartis Announces Launch of Amendment Process and Exchange Offer for its Existing Convertible Bonds Mechelen, Belgium , 26 September 202 2 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces the launch of the amendment process and exchange offer for its 4.00% convertible bonds due 2024 (the "Existing Convertible Bonds") as part of the...

PRESS RELEASE: 1 September 2022, 07:01 CEST Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin ™ Assay (CE-IVD) for Melanoma Patients Merlin helps identify melanoma patients who may safely forgo the sentinel lymph node biopsy Melanoma is the deadliest form of skin cancer 1 Biocartis to initia te commercialization in Europe of SkylineDx’s innovative Merlin Assay , ahead of the launch of a n Idylla™ version of the test Mechelen, Belgium , 1 September 202 2 –...

PRESS RELEASE: 24 August 2022, 07:00 CEST Biocartis Obtains ISO 27001 C ertification for Information Security Management Mechelen, Belgium, 24 August 2022 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces it has obtained the ISO 27001 certification for the design, development, maintenance, service provision and support of the Idylla™ platform and associated customer-facing software . Commenting...

PRESS RELEASE : 20 June 2022, 07:00 CEST Biocartis Announces Launch of its Rapid CE - marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Idylla™ GeneFusion Panel available as rapid CE-marked IVD lung cancer testing solution for laboratories , with results within 180 minutes 10% to 20% of advanced lung cancer patients don’t receive the appropriate targeted therapy d ue to slow turnaround time of many current testing methods , leading to a delayed...